Cinven and Linden Capital Partners have made a strategic investment in Regenity Biosciences to support the company's growth and innovation in the regenerative medicine sector, leveraging its operational strengths and expanding its manufacturing capabilities.

Information on the target

Regenity Biosciences, founded in 1997 and headquartered in New Jersey, USA, is a leading global developer and manufacturer of bioresorbable technologies. With nearly three decades of experience, the Company has advanced innovative biomaterials that facilitate the body’s natural healing processes for tissue and bone regeneration across various clinical areas, including dental, orthopaedic, spine, neurosurgery, advanced wound care, sports medicine, ENT, and nerve repair. Currently, Regenity employs over 250 professionals and serves more than 125 customers with an extensive portfolio of over 80 product lines worldwide.

Regenity boasts a robust history of product development and manufacturing, evidenced by its broad array of FDA-approved solutions and a portfolio of over 100 patents. The Company has treated more than 5 million patients in 2025 alone and over 30 million patients since its inception. Its vertically integrated approach combines proprietary materials science with deep technical expertise, aiming to make a significant impact on patient outcomes by transforming breakthrough solutions from rapid prototyping into commercial realities.

Industry overview in the target’s specific country

The healthcare industry in the United States is one of the largest and most advanced globally, characterized by continuous innovation and significant investment in research and development. The regenerative medicine sector, in particular, has witnessed remarkable